Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Combined hormonal contraceptives (CHCs) - Important Safety Information from the Marketing Authorisation Holders as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
28/01/2014
Problem Or Issue:
Important Safety Information communication on the difference in risk of thromboembolism between products, the importance of individual risk factors and to remain vigilant for signs and symptoms of combined hormonal contraceptives (CHCs). This information is being provided jointly by the following Marketing Authorisation Holders: Bayer Ltd, Clonmel Healthcare Ltd, Janssen-Cilag Ltd, Merck Sharp & Dohme (MSD), Pfizer Healthcare Ireland, Rowex Ltd and Teva Pharmaceuticals Ireland (on behalf of Teva Pharma BV).
Important Safety Information - combined hormonal contraceptives (CHCs)
« Back
Date Printed: 19/05/2024